【摘要】 目的 探讨应用特拉唑嗪联合洛美沙星治疗慢性前列腺炎/慢性盆腔痛综合征(CP/CPPS)病人的临床疗效。方法 有症状的病人或盆腔区域有疼痛的患者共80例，病程至少3个月,80例患者中除8例外，均接受特拉唑嗪联合洛美沙星治疗6周，外加6周的随访，观察从开始治疗到6周治疗全部结束后治疗的效果，并评价患者NIH-CPSI症状评分及EPS中WBC的变化差异有无显著性。结果 应用特拉唑嗪联合洛美沙星治疗慢性前列腺炎/慢性盆腔痛综合征(CP/CPPS) 用药6周后， 总体上NIH-CPSI症状评分较治疗前有明显改善，经统计学处理差异有显著性(P<0.05)，且无明显不良反应；72例中,共治愈44例(61.1%)，好转21例(29.2%)，无效7例(9.7%)，总有效率为90.3%。结论 应用特拉唑嗪联合洛美沙星治疗慢性前列腺炎/慢性盆腔痛综合征(CP/CPPS)，疗效显著，副作用小。

    【关键词】 慢性前列腺炎(CP/CPPS)；肾上腺素能α受体阻滞剂

    α1-blocker terazosin combination with antibiotics lomefloxacin in the treatment of chronic prostatitis

    CHEN Chu-hong,GONG Min,HU Wei,et al.

    Department of Nanhui Central Hospital，Shanghai 201300,China

    【Abstract】 Objective To study the effect and mechanism of α1-blockers combination with antibiotic lomefloxacin in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).Methods The study population of patients consist of 80 men with symptoms of discomfort or pain in the pelvic region for at least 3-month period within the previous 6 months. The treated group patients with α1 -blocker terazosin and antibiotic lomefloxacin for 6 weeks and followed up by 6 weeks. And estimate the effect of this combination treatment has also been made to evaluate NIH-CPSI scores and the varieties of white blood cell counts (WBC) in expressed prostatic secretions (EPS) whether they have a statistics significance.Results NIH-CPSI scores were significantly improved in comparison with pretreatment, and white blood cell counts (WBC) had also significantly changed.Conclusion α1-blocker terazosin combination with antibiotics lomefloxacin can improve the symptoms of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and the effect is significant with few side effects. ......